Stem cell-derived extracellular vesicles as senotherapeutics

12Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Cellular senescence (CS) is recognized as one of the hallmarks of aging, and an important player in a variety of age-related pathologies. Accumulation of senescent cells can promote a pro-inflammatory and pro-cancerogenic microenvironment. Among potential senotherapeutics are extracellular vesicles (EVs) (40–1000 nm), including exosomes (40–150 nm), that play an important role in cell-cell communications. Here, we review the most recent studies on the impact of EVs derived from stem cells (MSCs, ESCs, iPSCs) as well as non-stem cells of various types on CS and discuss potential mechanisms responsible for the senotherapeutic effects of EVs. The analysis revealed that (i) EVs derived from stem cells, pluripotent (ESCs, iPSCs) or multipotent (MSCs of various origin), can mitigate the cellular senescence phenotype both in vitro and in vivo; (ii) this effect is presumably senomorphic; (iii) EVs display cross-species activity, without apparent immunogenic responses. In summary, stem cell-derived EVs appear to be promising senotherapeutics, with a feasible application in humans.

Cite

CITATION STYLE

APA

Rudnitsky, E., Braiman, A., Wolfson, M., Muradian, K. K., Gorbunova, V., Turgeman, G., & Fraifeld, V. E. (2024, August 1). Stem cell-derived extracellular vesicles as senotherapeutics. Ageing Research Reviews. Elsevier Ireland Ltd. https://doi.org/10.1016/j.arr.2024.102391

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free